Neurocrine Sues Zydus to Guard Ingrezza’s New Sprinkle Form

Zydus Lifesciences Ltd.’s proposed copies of Neurocrine Biosciences Inc.’s Ingrezza Sprinkle infringe 20 patents related to the drug that treats involuntary movements from conditions like Huntington’s disease, two federal lawsuits said.

Neurocrine filed suits on April 25 in both the District of Delaware and District of New Jersey accusing Zydus of infringing the patents with its generic versions of the sprinkled-granules formulation of valbenazine, Ingrezza Sprinkle’s active ingredient. The suit belongs in Delaware, Neurocrine said, adding that it also filed the New Jersey complaint “out of an abundance of caution.”

Neurocrine in November 2023 settled with Zydus in several Delaware ...